Trials / Completed
CompletedNCT02406274
Use of Contrast Enhanced Spectral Mammography (CESM) for Women With Palpable Breast Abnormalities
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 249 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Female
- Age
- 25 Years
- Healthy volunteers
- Not accepted
Summary
Contrast Enhanced Spectral Mammography (CESM) is an advanced form of mammography which is performed after injection of contrast or dye into a vein in the arm. This dye is the same dye that is used for CT scans. This type of mammogram includes a regular mammogram as well as additional pictures with the dye. This particular study is being done to determine if by adding the dye in the veins the investigators are better able to identify the cause of the lump than if they just did the regular mammogram alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Contrast Enhanced Spectral Mammography (CESM) | Women presenting to MSKCC with a palpable abnormality within the breast either self palpated \& or palpated by their physician will be offered CESM instead of FFDM alone. The breast imager assigned to care for the patient will interpret the low energy images (including any additional views they routinely obtain) \& record their findings. They will then interpret the CESM \& record those results. As per standard of care, the patient will have a targeted ultrasound as well. Appropriate clinical recommendations will be made. In patients with no specific imaging findings, follow-up will be determined by the degree of suspicion of the palpable finding \& will either be called negative \& followed clinically if not suspicious, or will go on to MRI , percutaneous biopsy by a surgeon or surgical biopsy if suspicious. |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2024-06-27
- Completion
- 2024-06-27
- First posted
- 2015-04-02
- Last updated
- 2024-06-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02406274. Inclusion in this directory is not an endorsement.